A validated high-performance liquid chromatographic method for the determination of moclobemide and its two metabolites in human plasma and application to pharmacokinetic studies

Biomedical Chromatography

Volumn 21, Issue 9, 2007, Pages 958-966

  Plenis, Alina ^a   Chmielewska, Aleksandra ^a   Konieczna, Lucyna ^a   Lamparczyk, Henryk ^a  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

Liquid liquid extraction; Moclobemide; p chloro N ( 2 morpholinoethyl)benzamide N oxide (Ro 12 5637); p chloro N 2 (3 oxomorpholino)ethyl benzamide (Ro 12 8095); Pharmacokinetics; RP HPLC determination

Indexed keywords

ALKALINITY; AMIDES; BIOMOLECULES; CHROMATOGRAPHIC ANALYSIS; DICHLOROMETHANE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; PHARMACOKINETICS; PLASMA (HUMAN); SOLVENT EXTRACTION;

BENZAMIDES; HIGH-PERFORMANCE LIQUID CHROMATOGRAPHIC METHODS; LIQUID-LIQUID EXTRACTION; MOCLOBEMIDE; N-OXIDES; P-CHLORO-N-(-2-MORPHOLINOETHYL)BENZAMIDE-N′-OXIDE (RO 12-5637); P-CHLORO-N-[2-(3-OXOMORPHOLINO)ETHYL]-BENZAMIDE (RO 12-8095); REVERSED-PHASE HIGH PERFORMANCE; REVERSED-PHASE HIGH-PERFORMANCE LIQUID CHROMATOGRAPHIC METHOD DETERMINATION;

METABOLITES;

4 CHLORO N [2 (3 OXOMORPHOLINO)ETHYL]BENZAMIDE; 4 [2 (4 CHLOROBENZAMIDO)ETHYL]MORPHOLINE 4 OXIDE; ACETONITRILE; DICHLOROMETHANE; MOCLOBEMIDE; PHENACETIN; PHOSPHORIC ACID;

ADULT; ALKALINITY; ANALYTIC METHOD; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG METABOLISM; DRUG STRUCTURE; FEMALE; HUMAN; HUMAN EXPERIMENT; LIQUID LIQUID EXTRACTION; MALE; NORMAL HUMAN; PH; RELIABILITY; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SENSITIVITY AND SPECIFICITY; SINGLE DRUG DOSE; SPECTROPHOTOMETRY; STANDARD; TIME TO MAXIMUM PLASMA CONCENTRATION; ULTRAVIOLET RADIATION; VALIDITY;

EID: 34548015895     PISSN: 02693879     EISSN: 10990801     Source Type: Journal    
DOI: 10.1002/bmc.840     Document Type: Article

References (27)

1. Adikwu MU and Ofokansi KC. Spectrophotometric determination of moclobemide by charge-transfer complexation, Journal of Pharmaceutical and Biomedical Analysis 1997; 16: 529-532.
2. Amini H, Shahmir B and Ahmadiani A. Determination of moclobemide in human plasma by high-performance liquid chromatography with spectrophotometric detection. Journal of Chromatography B 2004; 807: 271-275.
3. Bonnet U. Moclobemide: therapeutic use and clinical studies. CNS Drug Reviews 2003; 1: 97-140.
4. Fulton B and Benfield P. Moclobemide. An uptake of its pharmacological properties and therapeutic use. Drugs 1996; 52: 450-474.
5. Gaillard Y and Pépin G. Moclobemide fatalities: report of two cases and analytical determinations by GC-MS and HPLC-PDA after solid-phase extraction. Forensic Science International 1997; 87: 239-248.
6. Geschke R, Köner J and Eggers H. Determination of the new monoamine oxidase inhibitor moclobemide and three of its metabolites in biological fluids by high-performance liquid chromatography. Journal of Chromatography 1987; 420: 111-120.
7. Gex-Fabry M, Balant-Gorgia AE and Balant LP. Potential of concentration monitoring data for a short half-life drug: Analysis of pharmacokinetic variability for moclobemide. Therapeutic Drug Monitoring 1995; 17: 39-46.
8. Gram LF, Guentert TW, Grange S, Vistisen K and Brøsen K. Moclobemide, a substrate of CYP2C19 and an inhibitor of CYP2C19, CYP2D6, and CYP1A2: A panel study. Clinical Pharmacology and Therapeutics 1995; 57: 670-677.
9. Guentert TW, Tucker G, Korn A, Pfefen JP, Haefelfinger P and Schoerlin MP. Pharmacokinetics of moclobemide after single and multiple oral dosing with 150 milligrams 3 times daily for 15 days. Acta Psychiatrica Scandinavica (Suppl. 360) 1990; 82: 91-93.
10. Härtter S, Dingemanse J, Baier D, Ziegler G and Hiemke Ch. The role of cytochrome P450 in the metabolism of moclobemide. European Neuropsychopharmacology 1996; 6: 225-230.
11. Hoskins JM, Gross AS, Shenfield GM and Rivory LP. High-performance liquid chromatography-electrospray ionization mass spectrometry method for the measurement of moclobemide and two its metabolites in plasma. Journal of Chromatography B 2001a; 754: 319-326.
12. Hoskins J, Shenfield G, Murray M and Gross A. Characterization of moclobemide N-oxidation in human liver microsomes. Xenobiotica 2001b; 31: 387-397.
13. Hoskins JM, Shenfield GM and Gross AS. A modified HPLC method for rapid detection of moclobemide and its N-oxide metabolite in human urine. Journal of Liquid Chromatography and Related Technologies 2001c; 24: 521-529.
14. Huanda L, Xiaohua Y and Yanghua O. Studies on rapid analysis of toxicants and drugs in body fluids VII. RP-HPLC determination of moclobemide in serum. Yaowu Fenxi Zazhi 1997; 17: 3-5. Chemical Abstracts 1997; 127: 10 132884S.
15. Jauch R, Griesser E, Oesterhelt G, Arnold W, Meister W, Ziegler WH and Guentert TW. Biotransformation of moclobemide in humans. Acta Psychiatrica Scandinavica (Suppl. 360) 1990; 82: 87-90.
16. Kirchherr H and Kühn-Velten WN. Quantitative determination of forty-eight antidepressants and antipsychotics in human serum by HPLC tandem mass spectrometry: A multi-level, single-sample approach. Journal of Chromatography B, 2006; 843: 100-113.
17. Maguire KP, Norman TR, Davies BM and Burrows GD. Measurment of moclobemide, a new monoamine oxidase inhibitor, by gas chromatography with nitrogen-selective detection. Journal of Chromatography 1983; 278: 429-433.
18. Mayersohn M and Guentert TW. Clinical pharmacokinetics of the monoamine oxidase-A inhibitor moclobemide. Clinical Pharmacokinetics 1995; 29: 292-332.
19. Misztal G, Skibiński R, Olajossy M and Paw B. LC determination of moclobemide and three metabolites in plasma. Journal of Pharmaceutical and Biomedical Analysis 2002; 30: 1277-1285.
20. Ponds G, Schoerlin MP, Tam YK, Moran C, Pfefen JP and Francoual C. Moclobemide extraction in human breast milk. British Journal of Clinical Pharmacology 1990; 29: 27-31.
21. Raaflaub J, Haefelfinger P and Trautmann KM. Single-dose pharmacokinetics of the MAO-inhibitor moclobemide in man. Arzneimittelforschung 1984; 34: 80-82.
22. Rakic A, Miljkovic B, Pokrajac M and Vacicevic. High-performance liquid chromatographic method for the determination of moclobemide and its two major metabolites in human plasma. Journal of Pharmaceutical and Biomedical Analysis 2006; doi: 10.1016/j.jpba.2006.10.032.
23. Skibiński R and Misztal G. Determination of moclobemide, paroxetine, and fluvoxamine in tablets by HPLC. Acta Poloniae Pharmaceutica Drug Research 2001; 58: 97-100.
24. Stefan RI, Baiulescu GE and Aboul-Enein HY. Moclobemide-selective membrane electrode and its pharmaceutical applications. Talanta 1996; 43: 1171-1175.
25. Vallès B,. Coassolo Ph, De Sousa G, Aubert C and Rahmani R. In vitro hepatic biotransformation of moclobemide (Ro 11-1163) in man and rats. Xenobiotica 1993; 23: 1101-1111.
26. Wiesal FA, Raaflaub J and Kettler R. Pharmacokinetics of oral moclobemide in healthy human subjects and effects on MAO-activity in platelets and extraction of urine monoamine metabolites. European Journal of Clinical Pharmacology 1985; 28: 89-95.
27. Yamada M and Yasuhara H. Clinical pharmacology of MAO inhibitors: Safety and future. Neurotoxicology 2004; 25: 215-221.